Clinical Trial Update: Ranibizumab and the Risk of Arterial Thromboembolic Events [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating ranibizumab in age-related macular degeneration and related cardiovascular conditions was terminated. The update notes the study concer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Cerebrovascular Disorders
• Coronary Artery Disease

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Ural State Medical University | Conditions: Age-related Macular Degeneration, Coronary Artery Disease | Phase 4 | Status: TERMINATED